Skip to NavigationSkip to content

News

0
Aubiago
Genzyme sales and MS franchises lift French firm’s financial performance
0
$33 per share offer dismissed as ‘inadequate’
0
Teams up with Japanese pharma company to study potential for new immunotherapy combinations
0
Daklinza
Healthcare watchdog criticised for excluding major patient groups from treatment

Features

Antibiotic resistance

Can pharma avoid what experts have dubbed ‘antibiotic armageddon’?